HLFNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
HERBALIFE LTD.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$13.88−0.72 (-4.93%)
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- 9.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
77.9%−1.4 pts over 5 years
Operating margin
9.5%−2.0 pts over 5 years
Net margin
4.5%−2.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.9% | -1.1% | -1.9% | +1.2% | |
| Gross profit | +0.9% | -0.9% | -2.2% | +0.8% | |
| Operating income | +24.6% | -4.1% | -5.6% | -1.9% | |
| Net income | -10.2% | -10.8% | -9.3% | -3.9% | |
| EPS, diluted | -12.0% | -12.0% | -4.5% | +1.0% | |
| Free cash flow | +54.8% | +8.8% | -13.3% | -7.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 364.1% | -59.8% | -34.7% | |
| Return on assets | 10.3% | 12.9% | 8.3% | |
| Current ratio | 1.85 | 1.58 | 1.13 | |
| Debt to equity | 7.38 | -2.84 | -3.87 | |
| Net debt to EBITDA | 1.06× | 1.86× | 2.72× | |
| Interest coverage | 4.6× | 4.8× | 2.2× | |
| Inventory turnover | 2.4× | 2.5× | 2.3× | |
| Capex to revenue | 3.2% | 2.0% | 1.6% | |
| Diluted shares | 172M | 135M | 104M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Herbalife generated $1.79B from operations and spent $1.83B on capital expenditure, dividends and share buybacks. 35% of that went back into the business.
Generated
$1.79B
Used
$1.83B
Capital expenditure$645.20M35%Dividends$00%Share buybacks$1.19B65%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin4.5%
×Asset turnover1.83×
×Equity multiplier-4.19×
=Return on equity, FY2025-34.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 4.5% | 1.83× | -4.19× | -34.7% |
| FY2024 | 5.1% | 1.80× | -2.97× | -27.3% |
| FY2023 | 2.8% | 1.83× | -2.38× | -12.2% |
| FY2022 | 6.2% | 1.87× | -2.09× | -24.2% |
| FY2021 | 7.7% | 1.97× | -2.62× | -39.8% |
| FY2020 | 6.7% | 1.93× | -4.62× | -59.8% |
| FY2019 | 6.4% | 1.78× | -4.91× | -55.9% |
| FY2018 | 6.1% | 1.72× | -5.37× | -56.1% |
| FY2017 | 4.8% | 1.62× | -39.45× | -309.1% |
| FY2016 | 5.8% | 1.78× | 35.32× | 364.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$228.30M
- Cash generatingOperating cash flow above zero$333.30M
- Return on assets improvedROA up on the prior year9.1% → 8.4%
- Earnings backed by cashOperating cash flow above net income$333.30M vs $228.30M
- Less leverageLong-term debt to assets fell72.5% → 70.8%
- Better liquidityCurrent ratio rose0.93 → 1.13
- No dilutionShare count did not rise102M → 104M
- Gross margin improvedGross margin up on the prior year77.88% → 77.87%
- More efficientAsset turnover rose1.78 → 1.85